ATE533494T1 - Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür - Google Patents
Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafürInfo
- Publication number
- ATE533494T1 ATE533494T1 AT03743665T AT03743665T ATE533494T1 AT E533494 T1 ATE533494 T1 AT E533494T1 AT 03743665 T AT03743665 T AT 03743665T AT 03743665 T AT03743665 T AT 03743665T AT E533494 T1 ATE533494 T1 AT E533494T1
- Authority
- AT
- Austria
- Prior art keywords
- androgen receptor
- androgen
- osteoporosis
- treatment
- conditions
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000001132 Osteoporosis Diseases 0.000 abstract 3
- 102000001307 androgen receptors Human genes 0.000 abstract 3
- 108010080146 androgen receptors Proteins 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 3
- 201000004384 Alopecia Diseases 0.000 abstract 2
- 206010058359 Hypogonadism Diseases 0.000 abstract 2
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010049088 Osteopenia Diseases 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000019771 cognition Effects 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 208000024963 hair loss Diseases 0.000 abstract 2
- 230000003676 hair loss Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 230000036651 mood Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000001076 sarcopenia Diseases 0.000 abstract 2
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 238000009165 androgen replacement therapy Methods 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45373602P | 2002-02-28 | 2002-02-28 | |
| US42338102P | 2002-11-04 | 2002-11-04 | |
| PCT/US2003/003123 WO2003074449A2 (en) | 2002-02-28 | 2003-02-24 | Multi-substitued selective androgen receptor modulators and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533494T1 true ATE533494T1 (de) | 2011-12-15 |
Family
ID=33422848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03743665T ATE533494T1 (de) | 2002-02-28 | 2003-02-24 | Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7705182B2 (de) |
| EP (1) | EP1487458B1 (de) |
| JP (2) | JP5113979B2 (de) |
| KR (2) | KR101088352B1 (de) |
| CN (1) | CN1700923B (de) |
| AT (1) | ATE533494T1 (de) |
| ES (1) | ES2528764T3 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
| US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
| US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
| US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
| US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| CA2660570C (en) | 2006-08-24 | 2016-08-09 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| AU2008298901C1 (en) * | 2007-09-11 | 2013-10-03 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| CA2891005A1 (en) | 2007-09-28 | 2008-10-09 | Bind Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| EP2620157A3 (de) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Impfstoffnanotechnologie |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| JP2013516501A (ja) * | 2010-01-11 | 2013-05-13 | ジーティーエックス・インコーポレイテッド | マイボーム腺機能障害を治療する方法 |
| KR20130139218A (ko) | 2010-08-11 | 2013-12-20 | 아사히 가라스 가부시키가이샤 | 발수발유제 조성물 및 물품 |
| WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| CN110840870A (zh) | 2012-07-13 | 2020-02-28 | Gtx公司 | 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用 |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| CA2964371A1 (en) * | 2014-10-16 | 2016-04-21 | Gtx, Inc. | Methods of treating urological disorders using sarms |
| CN106748884B (zh) * | 2016-12-13 | 2021-08-20 | 山西振东制药股份有限公司 | 一种比卡鲁胺中间体的制备方法 |
| WO2019001171A1 (zh) * | 2017-06-27 | 2019-01-03 | 维眸生物科技上海有限公司 | 一种含磷化合物及其制备和应用 |
| CN109134533B (zh) * | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| EP3814272A4 (de) | 2018-05-11 | 2022-03-02 | Phosphorex, Inc. | Mikropartikel und nanopartikel mit negativen oberflächenladungen |
| KR20230084476A (ko) | 2020-10-08 | 2023-06-13 | 타르그이뮨 테라퓨틱스 아게 | 암의 치료를 위한 면역요법 |
| WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
| WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
| WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
| WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
| WO2024104422A1 (en) * | 2022-11-17 | 2024-05-23 | Vivavision Biotech, Inc. | Phosphorus-containing compounds for treating inflammatory bowel diesease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB136001A (en) | 1919-01-11 | 1919-12-11 | Frank Harrison | An Adjustable Angle, and Surface-marking Plate. |
| GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
| US3875229A (en) | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
| JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
| US4139638A (en) | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
| EP0002309B1 (de) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische und tierärztliche Zusammensetzungen |
| US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
| NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
| JPS57171904A (en) | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| US4633025A (en) | 1985-04-15 | 1986-12-30 | Miles Laboratories, Inc. | Method for preparing (+)R-2-methyl-hexane-1,2-diol |
| GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| GB8617652D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| US4977288A (en) | 1988-01-29 | 1990-12-11 | President And Fellows Of Harvard College | M-aminophenyltrialkylstannane |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| EP0748220A4 (de) | 1994-01-21 | 1997-09-10 | Sepracor Inc | Verfahren und zusammensetzungen zur behandlung von androgen-abhängigen krankheiten unter verwenddung von optisch reinem r-(-)casodex |
| US5609849A (en) | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
| PT800519E (pt) | 1994-12-22 | 2004-03-31 | Ligand Pharm Inc | Compostos moduladores de receptores de esteroides e metodos |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| JP2000513362A (ja) | 1996-06-27 | 2000-10-10 | リガンド・ファーマスーティカルス・インコーポレーテッド | アンドロゲン受容体モジュレーター化合物及び方法 |
| WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
| US6071957A (en) | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| US6492554B2 (en) | 2000-08-24 | 2002-12-10 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| US6160011A (en) | 1997-05-30 | 2000-12-12 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
| WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| RU2234920C2 (ru) | 1999-06-11 | 2004-08-27 | Уотсон Фармасьютикалс, Инк. | Введение непероральным путем андрогенных стероидов женщинам |
| EP1222459A4 (de) | 1999-10-14 | 2003-01-22 | Bristol Myers Squibb Co | Kristallographische struktur der bindungsstelle des androgenen rezeptors |
| EP1222165A2 (de) | 1999-10-19 | 2002-07-17 | Nobex Corporation | Verfahren zur asymmetrischen herstellung von enantiomeren von casodex und seiner derivate und zwischenprodukte davon |
| US6593492B1 (en) | 1999-10-27 | 2003-07-15 | Nobex Corporation | Resolution of intermediates in the synthesis of substantially pure bicalutamide |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| CA2413417A1 (en) | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
| RU2003102390A (ru) | 2000-06-28 | 2004-05-27 | Бристол-Маерс Сквибб Компани (Us) | Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения |
| DE60124322T2 (de) | 2000-08-24 | 2007-05-31 | University Of Tennessee Research Foundation, Knoxville | Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung |
| US6998500B2 (en) * | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| CA2469340A1 (en) | 2001-12-06 | 2003-06-19 | Gtx Inc. | Treating muscle wasting with selective androgen receptor modulators |
-
2003
- 2003-02-24 KR KR1020107017179A patent/KR101088352B1/ko active IP Right Grant
- 2003-02-24 US US10/371,155 patent/US7705182B2/en not_active Expired - Fee Related
- 2003-02-24 KR KR10-2004-7013479A patent/KR20040101251A/ko active IP Right Grant
- 2003-02-24 AT AT03743665T patent/ATE533494T1/de active
- 2003-02-24 EP EP03743665A patent/EP1487458B1/de not_active Expired - Lifetime
- 2003-02-24 ES ES10010264.9T patent/ES2528764T3/es not_active Expired - Lifetime
- 2003-02-24 JP JP2003572923A patent/JP5113979B2/ja not_active Expired - Fee Related
- 2003-02-24 CN CN038096064A patent/CN1700923B/zh not_active Expired - Fee Related
-
2010
- 2010-05-12 JP JP2010110335A patent/JP2010180245A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1487458B1 (de) | 2011-11-16 |
| KR20100103662A (ko) | 2010-09-27 |
| US7705182B2 (en) | 2010-04-27 |
| EP1487458A4 (de) | 2006-07-26 |
| ES2528764T3 (es) | 2015-02-12 |
| KR20040101251A (ko) | 2004-12-02 |
| JP2005526741A (ja) | 2005-09-08 |
| JP5113979B2 (ja) | 2013-01-09 |
| JP2010180245A (ja) | 2010-08-19 |
| CN1700923B (zh) | 2011-06-15 |
| KR101088352B1 (ko) | 2011-11-30 |
| EP1487458A2 (de) | 2004-12-22 |
| CN1700923A (zh) | 2005-11-23 |
| US20060183931A1 (en) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE533494T1 (de) | Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür | |
| TW200407280A (en) | N-bridged selective androgen receptor modulators and methods of use thereof | |
| TW200503711A (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
| TW200420571A (en) | Halogenated selective androgen receptor modulators and methods of use thereof | |
| TW200502249A (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
| WO2003074449A3 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
| TW200613252A (en) | Metabolites of selective androgen receptor modulators and methods of use thereof | |
| WO2003074473A3 (en) | Irreversible selective androgen receptor modulators and methods of use thereof | |
| TW200512180A (en) | Large-scale synthesis of selective androgen receptor modulators | |
| TW200503729A (en) | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS | |
| BR0307981A (pt) | Compostos substituìdos de haloacetamida e azida e seus métodos de uso | |
| MXPA03001632A (es) | Moduladores receptores de androgeno selectivos y metodos para usar los mismos. | |
| MX2009000715A (es) | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. | |
| RS63204A (en) | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin | |
| GEP20094851B (en) | Selective androgen receptor modulators and methods of use thereof | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| BG108495A (en) | 5-ht receptor ligands and uses thereof | |
| DE602005021203D1 (de) | Gerät zum mischen und abgeben von knochenzement | |
| MXPA06000119A (es) | Profarmacos de moduladores receptores de androgenos selectivos y metodos de uso de los mismos. | |
| TW200502250A (en) | Treating androgen decline in aging male (ADAM)-associated conditions with SARMS | |
| WO2007081696A3 (en) | Treating androgen decline in aging male (adam)-associated conditions with sarms | |
| EA200401123A1 (ru) | Галогенацетамидные и азидзамещённые соединения и способы их применения | |
| BR0308076A (pt) | Modulares seletivos receptores de androgênio irreversìveis e seus métodos de uso | |
| MX2018002510A (es) | Combinacion farmaceutica para trastornos del estado de animo. | |
| MXPA05005337A (es) | Uso de moduladores de receptor de progesterona selectivos para el tratamiento de deficiencia de androgenos. |